Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?
- 23 November 2010
- journal article
- editorial
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (1), 157-163
- https://doi.org/10.1517/14656566.2011.534780
Abstract
The Bcr-Abl kinase inhibitor imatinib is the standard treatment for chronic myeloid leukaemia (CML). Some subjects with CML do not respond to, or are intolerant of, imatinib. Nilotinib and dasatinib were initially developed to treat these subjects, and were shown to be effective. They are now being trialled as initial ‘inib’ treatment for CML. The objective was to evaluate the recent Phase III clinical trials comparing nilotinib or dasatinib with imatinib in newly diagnosed CML. Nilotinib and dasatinib were shown to give a higher rate of complete cytogenic and major molecular responses than imatinib over 1 year. They should be considered as first choice in the treatment of subjects who develop CML. However, there are still major limitations to the populations with which these ‘inib’ drugs can be used, and how they can be used.Keywords
This publication has 19 references indexed in Scilit:
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’Leukemia & Lymphoma, 2010
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseJournal of Clinical Oncology, 2010
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemiaBlood, 2009
- Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of ImatinibClinical Cancer Research, 2008
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood, 2007
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALLNew England Journal of Medicine, 2006
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001